No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer
Scandinavian Journal of Urology · 2026
DOI: 10.2340/sju.v61.46892 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Scandinavian Journal of Urology, 2026. Verfasst von Sofia Lingefelt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Cystectomy, Neoplasm Recurrence, Local, Urethral Neoplasms, Urinary Bladder Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
The Gold standard treatment for muscle-invasive bladder cancer (MIBC) in medically fit patients is neoadjuvant chemotherapy (NAC), followed by radical cystectomy (RC), usually urethra-sparing. Swedish guidelines recommend yearly urethroscopies for 5 years post-RC to detect urethral recurrences (URs). Evidence is limited regarding optimal urethral surveillance in the NAC-era for patients with MIBC. The goal was to evaluate UR-frequency across NAC-response groups: complete response (CR), i.e. pT0N0M0, and Non-CR-responses (partial response, stable disease, and progressive disease), compared with cystectomy-only controls. Materials and methods: A multicenter retrospective cohort study including 241 patients with ≥T2 disease in clinical and/or pathological staging (post-RC), urothelial or mixed urothelial histology, and undergoing urethra-sparing cystectomy between 2010 and 2024. Data were retrieved from medical records and transferred into an ethically approved database. UR was biopsy-confirmed; time to UR was analyzed using Aalen–Johansen cumulative incidence functions with the Gray’s test.
Results
40% (50/123) of the NAC-patients were complete responders. Nine UR-events occurred (3.7%) in the total material. UR was observed in 3/123 (2.4%) NAC-treated and 6/118 (5.1%) in No-NAC patients (Gray’s, p = 0.291). No UR occurred among complete responders to NAC (0/50) versus 3/73 in non-complete responders (Gray’s, p = 0.150). Four UR-cases (44.4%) were symptom-detected (urethral bleeding).
Conclusions
The total absence of urethral recurrences in NAC- and RC-treated MIBC-patients with complete responses suggests that the current Swedish recommendation of yearly urethroscopies could be reviewed since a more individualized surveillance strategy based on NAC-response may reduce unnecessary procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden.
- Department of Urology, Västmanland Hospital, Västerås, Sweden.
- Department of Statistics, Umeå School of Business, Economics and Statistics, Umeå University, Umeå, Sweden.
- Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden. amir.sherif@umu.se.
ORCID-Profile: Farhood Alamdari, Johan Svensson, Amir Sherif
Zitieren
APA
Lingefelt, S., Nystrand, V., Alamdari, F., Svensson, J., & Sherif, A. (2026). No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer. Scandinavian Journal of Urology. https://doi.org/10.2340/sju.v61.46892
Vancouver
Lingefelt S, Nystrand V, Alamdari F, Svensson J, Sherif A. No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer. Scandinavian Journal of Urology. 2026. doi:10.2340/sju.v61.46892
BibTeX
@article{Lingefelt2026,
author = {Lingefelt, Sofia and Nystrand, Viktor and Alamdari, Farhood and Svensson, Johan and Sherif, Amir},
title = {No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer},
journal = {Scandinavian Journal of Urology},
year = {2026},
doi = {10.2340/sju.v61.46892}
}
EUVIMED